

1 **Analysis of opioid distribution before and after recreational marijuana legalization**
2 **in California**

3 Michelle N. Anyaehie, MBS¹, Christian Pardo, MBS¹, Elijah J Johnson, MBS¹, Chucks
4 Anachebe MBS¹, Brian J. Piper, PhD^{1,2}

5

6 ¹Geisinger Commonwealth School of Medicine, Scranton, PA 18590

7 ²Center for Pharmacy Innovation and Outcomes, Forty Fort, PA

8

9 525 Pine St, Scranton, PA 18510

10 Correspondence: Michelle N Anyaehie: manyaehie@som.geisinger.edu

11

12 Word count

- 13 ▪ Abstract: 193
- 14 ▪ Manuscript: 2,195
- 15 ▪ Figures: 4
- 16 ▪ Supplemental Figures: 2
- 17 ▪ Tables: 0

18

19

20

21

22

23

24

25

26

27

28

29

30

31 **Abstract**

32 The opioid epidemic has risen to an all-time high. Harm reduction and prevention
33 policies have not alleviated this crisis. Recent investigations have highlighted the
34 efficacy and safety of marijuana-based products for pain management. Providing
35 alternative pain treatment options may help mitigate the opioid epidemic. The
36 distribution of codeine, fentanyl, hydrocodone, morphine, and oxycodone per 100K
37 people and by 3-digit zip codes and overdose rates from 2014 to 2018 in California,
38 which legalized recreational marijuana in 2016, were compared to Texas, where
39 marijuana is functionally prohibited. Drug weights were obtained from the Automation of
40 Reports and Consolidated Orders System and converted to oral morphine milligram
41 equivalents. Overdose data was retrieved from the Centers for Disease Control's
42 WONDER database. California (-43.7%) and Texas (-27.3%) showed significant
43 reductions in cumulative opioid distribution from 2014 to 2018. Opioid distribution per
44 100K people decreased -38.9% in California relative to -26.4% in Texas. Opioid and
45 heroin overdoses increased between 1999 and 2019 by +11.6% in California but
46 +272.7% in Texas. This evidence supports marijuana legalization as a mitigating factor
47 to the opioid epidemic. Continued studies on safer pain management alternatives and
48 policies will help identify measures that help combat the opioid epidemic.

49
50
51

52 **Key words:** Marijuana, cannabis, opioid epidemic, medical marijuana, opioids, pain
53 management

54 Introduction

55 Under the Controlled Substance Act of 1970, marijuana is classified as a
56 schedule I drug along with heroin and ecstasy. Schedule I substances are defined as
57 having high abuse potential and no medical efficacy. Various opioids are listed as
58 schedule II drugs, which have limited medical use with a high abuse potential, and
59 certain opioid combination drugs are listed as schedule III (e.g., acetaminophen with
60 codeine). Here, the opioid distributions of fentanyl, oxycodone, morphine, hydrocodone,
61 and codeine, listed in order of decreasing potency (*List Of Opioids From Strongest To
62 Weakest - Addiction Resource, 2020*), as well as opioid overdose rates in California
63 after legalization of recreational marijuana have been analyzed. California legalized
64 medical marijuana in 1996 and recreational marijuana in 2016.

65 The opioid epidemic is characterized by a steep increase in opioid prescription
66 rates followed by a rise in opioid-related deaths in the early 1990s. Opioid prescriptions
67 quadrupled from 1998 to 2008 and resulted in alarming overdose rates (Jones et al.,
68 2018). Nationwide opioid prescription rates steadily increased from 2006 to 2012 but
69 started decreasing from 2013 to 2018 (*CDC Injury Center, 2020*), showing there has
70 been an effort to alleviate the crisis. Removing pain as the fifth vital sign, implementing
71 drug disposal programs, and returning unused medications are several measures that
72 have been enacted (Cabrera et al., 2019). However, these measures have had little to
73 no effect on opioid distribution and control of opioid-related deaths. In fact, there were
74 approximately 65,000 deaths in 2016, an increase of 21% from the year prior (Jones et
75 al., 2018). California reported six opioid related deaths per 100K people in 2018
76 (*California: Opioid-Involved Deaths and Related Harms | National Institute on Drug*

77 *Abuse (NIDA), 2020.*). Comparably, Texas reported five opioid related deaths per 100K
78 people in 2018 (*Texas: Opioid-Involved Deaths and Related Harms | National Institute*
79 *on Drug Abuse (NIDA), 2020*). The opioid prescription rate was 35.1 prescriptions per
80 100 persons in California (Huey & Apollonio, 2019) and 47.2 in Texas (*Texas: Opioid-*
81 *Involved Deaths and Related Harms | National Institute on Drug Abuse (NIDA), n.d.*) in
82 2018.

83 Due to stringent federal legislature, there has been little research deciphering the
84 effects of medical marijuana, particularly using products available at dispensaries, and
85 therefore the relationship between marijuana use and trends in opioid distribution and
86 narcotic overdoses has not been fully elucidated. However, California legalized
87 medicinal marijuana in 1996 and recreational marijuana in 2016. Recreational
88 dispensaries opened to individuals who were at least 21 years of age in January 2018.
89 As data demonstrating marijuana's success as an alternative to opioids is presented
90 (Blake et al., 2019; Boehnke et al., 2016; Kienzl et al., 2020; Lee et al., 2018; Sagy et
91 al., 2019; Ware et al., 2015)), resulting opioid trends can be analyzed. In this study,
92 opioid distribution rates in California, where medical marijuana and recreational
93 marijuana use was legalized, by zip code and per capita, were compared to Texas,
94 which has not legalized recreational or medical marijuana. Texas caps the percent
95 tetrahydrocannabinol at 0.5% and enrollment (3,519 in Dec, 2020) in their program
96 relative to state's population is modest (Sparber & Jones, 2021). We hypothesize that
97 there will be a greater decrease in opioid distribution in California following the change
98 in marijuana legislation than in Texas.

99 **Methods**

100 **Procedure**

101 The Drug Enforcement Administration's Automation of Reports and Consolidated
102 Orders System (ARCOS) Database is used to track controlled substances from
103 manufacture, through distribution channels to point-of sale at the level of hospitals,
104 pharmacies, practitioners, and teaching institutions. The data is organized in several
105 reports summarizing drug distribution by first three-digits of the zip code, per 100K
106 population gathered and includes summaries of purchases. Report 1, which reports
107 drug distribution by zip code, and Report 3, which reports quarterly drug distribution by
108 state per 100,000 population by gram were selected for analysis (*ARCOS Retail Drug
109 Summary Report - 2011 Reporting Period*, n.d.; Ighodaro et al., 2019). Fentanyl,
110 oxycodone, morphine, hydrocodone and codeine were chosen based on their familiarity
111 in the general population and inclusion in prior research (Cabrera et al. 2018; Ighodaro
112 et al. 2019; Piper et al. 2017). ARCOS data has been previously validated by comparing
113 results to a state Prescription Drug Monitoring Program which showed a satisfactory ($r =$
114 0.985) agreement (Piper et al., 2017).

115 The Center for Disease Control WONDER database was constructed to facilitate
116 access to public health information for state and local health departments and the
117 academic public health community (Friede et al., 1994). The mortality data was
118 extracted from WONDER as "Drug-induced causes" set as the underlying cause of
119 death with the Multiple Cause of Death ICD-10 codes T40.1- "Heroin" and T40.2- "Other
120 opioids". ICD-10 code T40.1 is limited to heroin induced deaths. ICD-10 code T40.2
121 excludes non-opioid narcotics, such as cocaine, opium, and LSD, and may include but

122 is not limited to codeine, fentanyl, hydrocodone, hydromorphone, morphine, oxycodone,
123 and tramadol. Total overdose rate includes heroin and other opioid induced deaths.

124 **Data Analysis**

125 The weights of five common opioids (codeine, fentanyl, hydrocodone, morphine,
126 and oxycodone) were converted to oral Morphine Milligram Equivalents (MME) (Piper et
127 al., 2018). Outliers were tested for using Grubbs' Test on GraphPad Prism. Heat maps
128 and graphs were constructed using Microsoft Excel and GraphPad Prism 8. Two-tailed
129 paired equal variance t-tests were performed using GraphPad Prism 8 software on zip
130 code distribution data to determine statistical differences with $p < 0.05$ considered
131 significant.

132 **Results**

133 **Opioid Distribution by Zip Code**

134 In both 2014 and 2018, California showed much more widespread and
135 substantial cumulative opioid distribution as seen in Fig. 1(A-B). In 2014, portions of
136 California surrounding the Bay Area and portions of Southern California had cumulative
137 opioid distributions as high as 1,388,000 MME and 900,000 MME, respectively. In
138 contrast, the highest distribution in Texas was 790,000 MME in the surrounding Dallas
139 area. Most of Texas had a distribution of 100,000 or less while most zip codes in
140 California ranged from 150,000 to 650,000 (Fig. 1A). However, in 2018, the largest
141 distributions in California dropped to 720,000 MME in the Bay Area and 525,000 MME
142 in Southern California, decreases of 50 and 40 percent respectively (Fig. 1B). The
143 surrounding Dallas area saw a decrease of 25 percent while most of Texas did not
144 show a comparable decrease (Fig. 1C). Both California ($p < 0.0001$) and Texas
145 ($p < 0.0001$) showed statistically significant decreases in opioid distribution, but California

146 had an over two-fold difference per zip code (162,476 versus 62,808 MME) over this
147 five-year span. This represents a -43.7% decrease in California relative to only -27.3%
148 in Texas (Fig. 2). There was an increase of 6,000 MME in a 16-zip code area of
149 Southern California near Glendale and Burbank. In this area, fentanyl, morphine, and
150 oxycodone saw 1.5, 2.4, and 1.8-fold increases respectively while codeine and
151 hydrocodone did not undergo appreciable changes (Fig. 1C).

152 **Opioid Distribution Per Capita**

153 Opioid distribution per capita decreased in both California and Texas from 2014
154 to 2018 (-38.9% and -26.4% respectively). The change in California was more linear for
155 all opioids while Texas experienced more variable change (Fig. 3). Distribution of all five
156 opioids in California decreased to a greater extent than their Texan counterparts
157 (hydrocodone -65.4%, fentanyl -50.3%, morphine -42.7%, oxycodone -32.4%, and
158 codeine -19.1%, Fig. 3). Individual opioid distribution changes in Texas showed much
159 more variability with hydrocodone, fentanyl, and morphine distribution decreasing (-
160 42.3%, -36.7%, and -27.8%), oxycodone remaining essentially unchanged (-0.5%), and
161 codeine distribution increasing 150.1% (Fig. 3).

162 **Overdose rates**

163 Overall, opioid related deaths increased in California (11.6%) and Texas
164 (272.7%) between 1999 and 2019. California showed a decline in deaths from non-
165 heroin opioids between 2014-2019 (Fig. 4A) while Texas had an increase in deaths
166 from 2014-2017 and then experienced a decline in 2018 (Fig. 4B). Heroin related
167 deaths have increased continuously in California (71.4%) and Texas (400%) between
168 1999 and 2019.

169 Discussion

170 The observed trends in opioid distribution by zip code and per capita in California
171 and Texas support recreational marijuana legalization as a practical measure to help
172 reduce prescription opioid use. The five years analyzed (2014 – 2018) show a greater
173 decrease in California than in Texas (Fig. 2). Opioid distribution per 100K people in
174 California decreased 38.9% from 2014-2018 while distribution in Texas decreased by
175 only 26.4% (Fig. 3). Similarly, heat map analysis (Fig. 1(A-B)) illustrates a greater
176 decrease in opioid distribution over large areas of California compared to Texas from
177 2014 to 2018. These findings are consistent with investigations showing fewer opioid
178 prescriptions written in states where medical marijuana laws are passed (Bradford &
179 Bradford, 2016). A similar study showed a significant correlation between increased
180 marijuana use as a treatment for chronic pain and reduced opioid use (Boehnke et al.,
181 2016), suggesting a potential public health benefit of replacing opioids with cannabis.

182 The drop in hydrocodone and increase in codeine and oxycodone distribution per
183 capita seen in Texas (Fig. 3) is consistent with previous data showing that oxycodone
184 and codeine increased by weight distribution from 2014 to 2017 specifically in Texas
185 (*Texas: Opioid-Involved Deaths and Related Harms | National Institute on Drug Abuse*
186 (*NIDA*), n.d.). The reclassification of hydrocodone in 2014 from a schedule III to a
187 schedule II may be a factor behind this trend (Bohnert et al., 2018; *Texas: Opioid-*
188 *Involved Deaths and Related Harms | National Institute on Drug Abuse (NIDA)*, n.d.).
189 Increased restrictions surrounding hydrocodone may have created an environment for
190 the distribution of oxycodone and codeine to rise as there were fewer powerful
191 analgesic options available, such as cannabis products.

192 The decreasing trends observed in California (Fig.3) may be explained by current
193 approaches to treating pain and the reduction in opioid use as a result of medicinal and
194 recreational marijuana legalization. Three-fifths (62%) of women surveyed in California
195 and Colorado with gynecological malignancies stated their interest in non-prescription
196 cannabis and 35.6% were interested in using cannabis under the guidance of
197 physicians. One-quarter (26.7%) of these patients reported already using non-
198 prescription cannabis products to manage various cancer related symptoms (Blake et
199 al., 2019).

200 California saw a decrease in overdose deaths after the legalization of marijuana
201 in 2016 and 2018 (Fig.4), whereas Texas, which has not legalized marijuana,
202 experienced a rise in deaths by overdose in 2016 and 2017 however a gradual
203 decrease in 2018 was also shown. Results from our data could be accounted for by the
204 implementation of laws across the U.S. designed to mitigate overdoses by limiting
205 opioid prescriptions and institutionalizing Prescription Drug Monitoring Programs
206 introduced in 2017 (McGinty et al., 2018). Prior research has found that any association
207 between medical marijuana and opioid overdoses is complicated (Bachhuber et al.,
208 2014; Kaufman et al., 2021; Shover et al., 2019), but further studies will help describe
209 the relationship between changing marijuana legislature and opioid overdoses.

210 Although harm reduction policies and medication-assisted treatments for opioid
211 dependence have increased in availability, (e.g. sterile syringe access programs and
212 methadone) (Bohnert et al., 2018), alternative pain management strategies must be
213 employed to decrease access and use of opioids to lower addiction and overdose rates.
214 States that enacted medical cannabis laws had a 24.8% reduction in opioid overdose

215 mortality which further decreased in the years following their implementation
216 (Bachhuber et al., 2014). Evidence supports the promotion of safer and less addictive
217 alternatives for analgesic relief, and implementation of laws that could reduce the
218 misuse and abuse of opioids.

219 There were a variety of limitations to our study. Limited research on recreational
220 and non-prescription marijuana for analgesic effects makes it difficult to make accurate
221 analysis and inferences. Most findings on cannabis and chronic pain refer to medical
222 cannabis, but patients have reported using recreational and non-prescription cannabis
223 for medical benefits (Blake et al., 2019). Surveys taken to assess the use of recreational
224 and non-prescription marijuana from dispensaries would help differentiate between
225 recreational and medicinal marijuana use. The data extracted from ARCOS presented a
226 further limitation as the census data used by the Drug Enforcement Administration is
227 from 2010. Including more control states and utilizing 2020 census data, when
228 available, might be beneficial in future studies (Andreae et al., 2016). In addition,
229 ARCOS does not account for mail-order pharmacies and internet pharmacies that ship
230 different prescription opioids across state lines, including the five opioids used in this
231 study (*California: Opioid-Involved Deaths and Related Harms | National Institute on*
232 *Drug Abuse (NIDA)*, n.d.). Lastly, statistics gathered from CDC WONDER database do
233 not provide specific details on overdose outcomes and includes overdoses from all
234 opioids, not just the five previously discussed. Overdose data from WONDER may also
235 be underestimated and accuracy varies from state to state as there is no standardized
236 national reporting practice (*California: Opioid-Involved Deaths and Related Harms |*
237 *National Institute on Drug Abuse (NIDA)*, n.d.; *Texas: Opioid-Involved Deaths and*

238 *Related Harms | National Institute on Drug Abuse (NIDA)*, n.d.; Kaufman et al., 2021).

239 However, both California and Texas were rated by the CDC as in the same “less than
240 good” category for death determination quality (Kaufman et al., 2021).

241 **Conclusion**

242 Prescription opioid distribution in California showed a greater decrease
243 compared to Texas (43.7% and 27.3% respectively). These findings suggest a
244 relationship between California’s marijuana legislation and the decreased opioid
245 distribution when compared to a state that has legislation prohibiting medicinal or
246 recreational marijuana use. As more states increase access to cannabis, trends in
247 opioid distribution and use, as well as opioid overdoses, must be further analyzed to
248 promote legislature to help combat the opioid epidemic.

249 **Author Contributions**

250 Michelle N Anyaehie conceived and designed the study, performed literature search
251 and review, authored drafts of the paper, analyzed the data and approved the final
252 manuscript.

253 Christian Pardo conceived and designed the study, performed literature search and
254 review, analyzed the data, prepared figures, authored drafts of the paper, and approved
255 the final manuscript.

256 Elijah J Johnson conceived and designed the study, performed literature search and
257 review, authored drafts of the paper, and approved the final manuscript.

258 Chucks Anachebe authored drafts of the paper and approved the final manuscript.

259 Dr. Brian Piper authored drafts of the paper, analyzed data, and approved the final
260 manuscript.

261 **Conflicts of Interest**

262 The authors do not report any conflicts of interest.

263 **Acknowledgments**

264 We would like to thank Elizabeth Kuchinski, MPH and Dan Kaufman, MBS at Geisinger
265 Commonwealth School of Medicine for their guidance and feedback throughout this
266 study.

267


268 **References**

- 269 Andrae, M. H., Rhodes, E., Bourgoise, T., Carter, G. M., White, R. S., Indyk, D., ... &
270 Rhodes, R. (2016). An ethical exploration of barriers to research on controlled
271 drugs. *The American Journal of Bioethics*, 16(4), 36-47.
- 272 *ARCOS Retail Drug Summary Report - 2011 Reporting Period*. (n.d.). Retrieved
273 January 27, 2021, from
274 https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/2011/index.html
- 275 Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical
276 cannabis laws and opioid analgesic overdose mortality in the United States, 1999-
277 2010. *JAMA internal medicine*, 174(10), 1668-1673.
- 278 Blake, E. A., Ross, M., Ihenacho, U., Figueroa, L., Silverstein, E., Flink, D., ... & Roman,
279 L. (2019). Non-prescription cannabis use for symptom management amongst
280 women with gynecologic malignancies. *Gynecologic oncology reports*, 30, 100497.
- 281 Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated
282 with decreased opiate medication use in a retrospective cross-sectional survey of
283 patients with chronic pain. *The Journal of Pain*, 17(6), 739-744.
- 284 Bohnert, A. S., Guy Jr, G. P., & Losby, J. L. (2018). Opioid prescribing in the United
285 States before and after the Centers for Disease Control and Prevention's 2016
286 opioid guideline. *Annals of internal medicine*, 169(6), 367-375.
- 287 Bradford, A. C., & Bradford, W. D. (2016). Medical marijuana laws reduce prescription
288 medication use in Medicare Part D. *Health Affairs*, 35(7), 1230-1236.
- 289 Cabrera, F. F., Gamarra, E. R., Garcia, T. E., Littlejohn, A. D., Chinga, P. A., Pinentel-
290 Morillo, L. D., ... & Piper, B. J. (2019). Opioid distribution trends (2006–2017) in the
291 US Territories. *PeerJ*, 7, e6272.
- 292 NIDA. 2020, April 3. California: Opioid-Involved Deaths and Related Harms. Retrieved
293 from [https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/california-opioid-involved-deaths-related-harms)
294 [state/california-opioid-involved-deaths-related-harms](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/california-opioid-involved-deaths-related-harms) on 2021, February 20
- 295 NIDA. 2020, April 3. Texas: Opioid-Involved Deaths and Related Harms. Retrieved from
296 [https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/texas-](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/texas-opioid-involved-deaths-related-harms)
297 [opioid-involved-deaths-related-harms](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/texas-opioid-involved-deaths-related-harms) on 2021, February 20
- 298 Friede, A., Rosen, D. H., & Reid, J. A. (1994). CDC WONDER: a cooperative
299 processing architecture for public health. *Journal of the American Medical*
300 *Informatics Association*, 1(4), 303-312.
- 301 Huey, J., & Apollonio, D. E. (2019). Review of Tobacco Policies on University of
302 California Campuses. *Californian Journal of Health Promotion*, 17(1), 24-30.
- 303 Ighodaro, E. O., McCall, K. L., Chung, D. Y., Nichols, S. D., & Piper, B. J. (2019).
304 Dynamic changes in prescription opioids from 2006 to 2017 in Texas. *PeerJ*, 7,
305 e8108.
- 306 Jones, G. H., Bruera, E., Abdi, S., & Kantarjian, H. M. (2019). The opioid epidemic in
307 the United States—overview, origins, and potential solutions. *Obstetrical &*
308 *Gynecological Survey*, 74(5), 278-279.
- 309 Kaufman, D. E., Nihal, A. M., Leppo, J. D., Staples, K. M., McCall, K. L., & Piper, B. J.
310 (2021). Opioid mortality following medical marijuana implementation in the United
311 States. *Pharmacopsychiatry*. 54: 1-5. In press.
- 312 Kienzl, M., Storr, M., & Schicho, R. (2020). Cannabinoids and opioids in the treatment of


- 313 inflammatory bowel diseases. *Clinical and translational gastroenterology*, 11(1).
- 314 Lee, G., Grovey, B., Furnish, T., & Wallace, M. (2018). Medical cannabis for
315 neuropathic pain. *Current pain and headache reports*, 22(1), 1-12.
- 316 *List Of Opioids From Strongest To Weakest - Addiction Resource*. (n.d.). Retrieved
317 January 27, 2021, from <https://www.addictionresource.net/blog/opioids-strongest-318-weakest/>
- 319 McGinty, E. E., Barry, C. L., Stone, E. M., Niederdeppe, J., Kennedy-Hendricks, A.,
320 Linden, S., & Sherman, S. G. (2018). Public support for safe consumption sites and
321 syringe services programs to combat the opioid epidemic. *Preventive*
322 *medicine*, 111, 73-77.
- 323 Piper, B. J., Shah, D. T., Simoyan, O. M., McCall, K. L., & Nichols, S. D. (2018). Trends
324 in medical use of opioids in the US, 2006–2016. *American journal of preventive*
325 *medicine*, 54(5), 652-660.
- 326 Sagy, I., Bar-Lev Schleider, L., Abu-Shakra, M., & Novack, V. (2019). Safety and
327 efficacy of medical cannabis in fibromyalgia. *Journal of clinical medicine*, 8(6), 807.
- 328 Shover, C. L., Davis, C. S., Gordon, S. C., & Humphreys, K. (2019). Association
329 between medical cannabis laws and opioid overdose mortality has reversed over
330 time. *Proceedings of the National Academy of Sciences*, 116(26), 12624-12626.
- 331 Sparber, S., Jones, A. (2020). Texas' medical marijuana program is one of the most
332 restrictive in the country. Advocates hope the Legislature will change that. *Texas*
333 *Tribune*. Accessed 2/20/2021 at: <https://www.texastribune.org/2021/01/04/texas-334-medical-marijuana-2021/>
- 335 *U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center*. (n.d.).
336 Retrieved January 27, 2021, from <https://www.cdc.gov/drugoverdose/maps/rxrate-337-maps.html>
- 338 Ware, M. A., Wang, T., Shapiro, S., Collet, J. P., Boulanger, A., Esdaile, J. M., ... &
339 O'Connell, C. (2015). Cannabis for the management of pain: Assessment of safety
340 study (COMPASS). *The Journal of Pain*, 16(12), 1233-1242.
- 341
- 342
- 343
- 344
- 345

346 **Figures**

A.




B.




347

C.




348

349 **Figure 1.** Total opioid distribution in California and Texas in Morphine Mg Equivalents
350 (MME) by zip code as reported to the Drug Enforcement Administrations Automation of
351 Reports and Consolidated Ordering System in 2014 (A) and 2018 (B). Percent change
352 from 2014 to 2018 (C).




353

354 **Figure 2.** Opioid distribution (\pm SEM) per zip code as reported by the Drug Enforcement
355 Administration's Automation of Reports and Consolidated Orders System. Morphine Mg
356 Equivalent: MME. * $p < .05$ versus 2014.




357

358 **Figure 3.** Per capita distribution of selected opioids from 2014 to 2018 as reported to
 359 the Drug Enforcement Administration’s Automation of Reports and Consolidated Orders
 360 System in California **(A)** and Texas **(B)**. The percent change from 2014 to 2018 is
 361 shown in the key.




362 **Figure 4.** Opioid overdose rates as reported by the CDC’s Wide Ranging Online Data
 363 for Epidemiologic Research (WONDER) from 1999 to 2019 in California **(A)** and Texas
 364 **(B)**. The percent change from 1999 to 2019 is listed in the key.



365

366 **Figure S1.** Cumulative change in opioid distribution as reported to the Drug
 367 Enforcement Administration's Automation of Reports and Consolidated Orders System
 368 in California and Texas from 2014 to 2018.



369

370 **Figure S2.** Opioid composition as reported to the Drug Enforcement Administration's
 371 Automation of Reports and Consolidated Orders System per state (California : CA,
 372 Texas: TX) in 2014 (top) and 2018 (bottom).